Patanjali's COVID drug claim: FIR against Ramdev, four others

Patanjali's COVID drug claim: FIR against Ramdev, four others

Speaking to media persons this morning, he said that while it is a good thing that Ramdev has given the country a new medicine, but it needs proper permission from the Ayush Ministry. However, the government's clinical trial registry only listed NIMS, Jaipur as a site for the study of only 120 patients.

The hospital where Ramdev is claiming to conduct a clinical trial of medicine was a quarantine centre, the Minister said, adding that many patients recovered in three days here, and hence it is wrong to talk of inventing a medicine which cures patients in seven days.

However, the AYUSH ministry expressed unawareness about the development and Patanjali was stopped from advertising the medicine within a few hours after its launch. "The clinical study was initiated/ conducted on 100 Covid -19 positive patients who were admitted in NIMS after obtaining due consent from all concerned individuals, from May 23 which lasted up to June 14", NIMS claimed.

Raj Kumar, chief medical officer of Meerut, said on Thursday: "We have no information about any such study, which can anyway not be conducted in a district without the CMO's knowledge".

Patanjali Ayurveda, while presenting "Coronil" medicine on Tuesday had claimed that it has found a cure for coronavirus infection.

Google launches Duo and Meet group video calls on smart displays
Meeting attendance - hosts will get finer control over meetings and will be able to see who attended and who did not. Already available on Zoom, Google will let users add custom images in the background, while making a call via Meet.

He said that Baba Ramdev did not take permission from the state government for conducting the clinical trials for the drug launched by his company, Hindustan Times (HT) reported. "These people were kept there only because they had arrived from some other states, but none of them ever showed any symptoms of Covid-19". It said that medicine should come to the ministry first.

On Wednesday, the Union ayush ministry had written back to Patanjali acknowledging receipt of the company's 11-page reply to Tuesday's notice, but did not make the reply public.

Balkrishna posted this letter on Twitter with a two-line comment in Hindi and English: "The end of the controversy of @moayush".

A day ago, the Uttarakhand government stated that Patanjali had only applied for a licence to produce an immunity-boosting drug that would prevent cough and cold, and not as a medicine to treat the novel coronavirus disease.

Related Articles